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Abstract A large group of mitochondrial disorders, ranging
from early-onset pediatric encephalopathic syndromes to late-
onset myopathy with chronic progressive external
ophthalmoplegia (CPEOs), are inherited as Mendelian disor-
ders characterized by disturbed mitochondrial DNA (mtDNA)
maintenance. These errors of nuclear-mitochondrial
intergenomic signaling may lead to mtDNA depletion, accu-
mulation of mtDNA multiple deletions, or both, in critical
tissues. The genes involved encode proteins belonging to at
least three pathways: mtDNA replication and maintenance,
nucleotide supply and balance, and mitochondrial dynamics
and quality control. In most cases, allelic mutations in these
genes may lead to profoundly different phenotypes associated
with either mtDNA depletion or multiple deletions.
Introduction
Mitochondria are essential organelles found in nearly all eukary-
otic cells (Vafai and Mootha 2012), where they are mainly re-
lated to energy metabolism. The most prominent role for mito-
chondria is to generate ATP through the respiratory chain (RC)
by means of oxidative phosphorylation (OXPHOS). However,
mitochondria also take part in a vast array of important bio-
chemical pathways including, among others, heat production,
apoptosis, generation and detoxification of reactive oxygen spe-
cies (ROS), intracellular Ca2+ regulation, steroid hormone and
heme synthesis and lipid metabolism (Wallace 2005).
The RC is composed of four multiheteromeric complexes
(CI-IV), which transfer the electrons extracted from nutrients
bymeans of sequential redox reactions to molecular oxygen to
form water. This process is coupled to the translocation of
proton across the IM by three of the four canonical respiratory
chain complexes (CI, CIII, and CIV), generating a proton
gradient, which is then exploited by ATP synthase (or com-
plex V, CV) to convert ADP into ATP.
Mitochondria are semi-autonomous organelles because they
have their own DNA (mitochondrial DNA, mtDNA), which
encodes for 13 essential subunits of CI, CIII, CIV, and CV
(Schon et al 2012), whereas all the other components of the
RC, and indeed all of the other ≈1500 polypeptides constituting
the mitochondrial proteome, are encoded by the nuclear genome.
Therefore, mitochondrial bioenergetics and related homeostatic
and execution pathways are under the double genetic control of
both nuclear and mtDNA. The genetic duality of mitochondrial
metabolism has relevant consequences for human pathology, as
mutations in either nuclear or mtDNA can lead to mitochondrial
dysfunction and disease. These genetic features explain why mi-
tochondrial disorders can be transmitted as dominant, recessive,
X-linked or maternally-inherited traits (Zeviani and Di Donato
2004). Hundreds of pathogenic mtDNA mutations have been
reported (MITO-MAP 2012). Whilst mtDNA in normal condi-
tions is essentially uniform, a condition called homoplasmy,most
of the pathogenic mutations of mtDNA co-exist with a variable
percentage of wild-type mtDNA, in a condition termed
heteroplasmy. Mutations of mtDNA or of OXPHOS-related nu-
clear genes can affect virtually every tissue in the body, and lead
to different phenotypes depending on the organ involved, intrin-
sic severity of the mutation, targeted gene, and, in case of
mtDNA mutations, heteroplasmy levels. Tissue and organ
Communicated by: Shamima Rahman
Presented at the Annual Symposium of the Society for the Study of
Inborn Errors of Metabolism, Rome, Italy, September 6–9, 2016
* Massimo Zeviani
mdz21@mrc-mbu.cam.ac.uk
1 MRC-Mitochondrial Biology Unit, MRC MBU, Wellcome Trust/
MRC Building, Hills Road, Cambridge CB2 0XY, UK
J Inherit Metab Dis
DOI 10.1007/s10545-017-0027-5
functions critically depend on adequate ATP production, espe-
cially when energy demand is high, like in neurons and muscle
fibers (Koopman et al 2013). This explains why primary disor-
ders of mitochondrial bioenergetics usually cause neurodegener-
ation and/or myopathy, often in combination, to determine
encephalomyopathies affecting children or adults. However,
many mitochondrial disorders also involve additional organs,
e.g., causing heart impairment (for instance cardiac failure due
to cardiomyopathy, or heart conduction defects), liver dysfunc-
tion, diabetes mellitus, or alterations in special senses or specific
districts, e.g. sensory-neural deafness, ophthalmoparesis (due to
weakness of the extrinsic eyemuscles), ptosis (drooping eyelids),
retinitis pigmentosa, and optic neuropathy causing blindness due
to degeneration of the optic nerve. Mutations in mtDNA can
affect specific proteins of the respiratory chain or the in situ,
autochthonous synthesis of mitochondrial proteins as a whole
(when mutations or deletions involve tRNA or rRNA genes)
and can be in turn classified into large-scale rearrangements
(i.e., partial deletions or duplications) and point mutations. Both
groups have been associated with well-defined clinical syn-
dromes. Whilst single large-scale rearrangements are usually
sporadic, point mutations are tipically maternally inherited.
Large-scale rearrangements include several genes and are invari-
ably heteroplasmic. In contrast, point mutations may be
heteroplasmic or homoplasmic, the latter being characterized
by incomplete penetrance. (e.g., Leber’s hereditary optic
neuropathy).
In addition to sporadic or maternally inherited disorders due
to mutations of the mitochondrial genome, mitochondrial dis-
eases can also be transmitted asMendelian traits. Here, we shall
focus on those Mendelian disorders that alter the stability and
the integrity of mtDNA. In 1989, Zeviani and colleagues de-
scribed an Italian family with adult-onset mitochondrial myop-
athy characterized by chronic progressive external
ophthalmoplegia, CPEO, and inherited in an autosomal domi-
nant fashion (Zeviani et al 1989). Maternal inheritance was
excluded because the male patients also transmitted the disease
to their offspring. Since then, many additional autosomal dom-
inant CPEO families have been described. A second group of
syndromes, characterized by infantile myopathy or
hepatopathy, was then associated with depletion of mitochon-
drial DNA in affected tissues (Moraes et al 1991). Multiple
deletions and depletion of mitochondrial DNAwere also found
in skeletal muscle in a complex, multisystem syndrome com-
biningmuscle, brain, and gastrointestinal symptoms (mitochon-
drial neurogastrointestinal encephalomyopathy or MNGIE)
(Hirano et al 1998). Finally, mutations in the gene encoding
the DNA polymerase gamma (POLG), the master enzyme of
mitochondrial DNA replication, were found in severe, early-
onset neurologic disorders, namely Alpers-Huttenlocher
hepatopathic poliodystrophy, sensory-ataxia neuropathy with
dysarthria and ophthalmoplegia, and spinocerebellar ataxia-
epilepsy syndrome (Naviaux and Nguyen 2005).
Over the last decade, an increasing number of genes have
been identified in association with mtDNA multiple deletions
or depletion with variable phenotypes hallmarked by
syndromic CPEO, encephalomyopathy, and cardiomyopathy.
The vast majority of them involve proteins with a role in the
mtDNA replisome (POLG and 2, TWNK, DNA2, MGME1)
or dNTP supply for mtDNA synthesis (TP, TK2, DGUOK,
RRM2B, SUCLA2, SUCLG1). A novel category of proteins
involved in accumulation of mtDNAmultiple deletions is rep-
resented by OPA1 and MFN2, which are part of the complex
machinery regulating mitochondrial dynamics, specifically
mitochondrial fusion; and paraplegin and AFG3L2, which
play an important role in the protein quality control of
mitochondria.
Clinical features
Autosomal disorders classified as defects of mtDNA mainte-
nance due to disturbed nuclear-mitochondrial intergenomic
communication can be associated with the accumulation of
mtDNA large-scale rearrangements (mtDNA multiple dele-
tions) or by severe reduction of the mtDNA copy number
(mtDNA depletion syndromes) (Spinazzola and Zeviani
2005). The most frequent clinical presentations (Table 1) are:
(1) adult-onset encephalomyopathy, defined clinically by
CPEO, genetically by autosomal dominant or recessive
transmission, and molecularly by the presence of multi-
ple deletions of mtDNA.
(2) an autosomal recessive multisystem disorder known as
mitochondrial neurogastrointestinal encephalomyopathy
(MNGIE), characterized by combined accumulation of
multiple deletions and partial depletion of mtDNA.
(3) a spectrum of recessive neurologic syndromes ranging
from typical infantile hepatopathic poliodystrophy
(Alpers-Huttenlocher syndrome) to juvenile-onset senso-
ry-ataxia neuropathy, dysarthria, and ophthalmoplegia
(SANDO) to a combination of spinocerebellar ataxia
and epilepsy (SCAE) with or without external
ophthalmoplegia.
(4) early-onset, organ-specific autosomal recessive syn-
dromes associated with profound mtDNA depletion.
Autosomal dominant chronic progressive external
ophthalmoplegia (adCPEO) CPEO is frequent in mitochon-
drial disorders. The clinical hallmark is extraocular muscle
involvement; all patients have ptosis with limitation of eye
movements. The first symptoms typically appear when pa-
tients are 20 to 40 years old. Generalized muscle weakness
is frequently present. Additional features vary among families;
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they may include ataxia, sensorineural hearing loss, cataracts,
hypogonadism, parkinsonism, and psychiatric abnormalities
consisting of severe depression and avoidant personality.
Dysphagia, dysphonia, weakness of facial muscles, and pe-
ripheral neuropathy may be prominent symptoms in some
families. At rest, elevated levels of plasma lactate are detected
only in severely affected patients. Symptoms seem to progress
with age. Muscle biopsies show ragged-red fibers due to the
subsarcolemmal accumulation of abnormal mitochondria. In
addition, the histochemical reaction for cytochrome c oxidase
(COX, complex IV) is decreased or absent in scattered fibers,
and neurogenic changes may also be observed .
Biochemically, the activities of mtDNA-related respiratory
complexes (complex I, III, IV, and V) in muscle homogenate
can range from normal to about 50% of the controls' mean
(Servidei et al 1991). Presymptomatic patients appear normal
but often have laboratory, electrophysiological, morphologi-
cal, and biochemical features of a subclinical mitochondrial
encephalomyopathy. Autosomal dominant optic atrophy has
been reported in association with CPEO and multiple mtDNA
deletions. Additional signs included deafness, ataxia, axonal
sensory-motor polyneuropathy, and mitochondrial myopathy
with cytochrome c oxidase negative and ragged red fibers
(Yu-Wai-Man et al 2010).
Table 1 Genes and phenotypes
affecting mtDNA maintenance Gene mtDNA alteration Inheritance Main clinical phenotype OMIM
SLC25A4 Multiple deletions AD ad/arCPEO 157640/258450
Multiple deletions AR myopathy and cardiomyopathy 615418
Depletion AD myopathy and cardiomyopathy
TWNK Multiple deletions AD adCPEO 609286
Multiple deletions AR IOSCA 271245
Depletion AR Alpers-like
POLG Multiple deletions AD adCPEO 157640
Multiple deletions AR arCPEO 258450
Depletion AR Alpers-Huntenlocher 203700
Multiple deletions AR SANDO/SCAE 607459
POLG2 Multiple deletions AD adCPEO 610131
TFAM Depletion AR Hepatocerebral syndrome 617156
MGME1 Multiple deletions AR arCPEO 615076
DNA2 Multiple deletions AD adCPEO 615156
RNASEH1 Multiple deletions AR arCPEO 616479
RRM2B Multiple deletions AD adCPEO 613077
Depletion AR myopathy and tubulopathy 612075
TK2 Depletion AR myopathy 609560
Multiple deletions AR arCPEO 617069
DGUOK Depletion AR Hepatocerebral syndrome 251880
Multiple deletions AR Myopathy with or w/o CPEO 617070
Multiple deletions AR lower motor neuron syndrome
MPV17 Depletion AR Hepatocerebral syndrome 256810
Multiple deletions AR arCPEO, leukoencephalopathy and
parkinsonism
OPA1 Multiple deletions AD DOA 165500
Multiple deletions AD DOA plus 125250
MFN2 Multiple deletions AD DOA plus 608507
SPG7 Multiple deletions AR arCPEO and ataxia 602783
AFG3L2 Multiple deletions AD arCPEO and ataxia 604581
TYMP Multiple deletions and
depletion
AR MNGIE 603041
SUCLA2 Depletion AR Hepatocerebral syndrome 612073
SUCLG1 Depletion AR Hepatocerebral syndrome 245400
ABAT Multiple deletions AR Encephalomyopathy 613163
FBXL4 Depletion AR Encephalomyopathy 615471
GFER Multiple deletions AR myopathy 613076
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Autosomal recessive chronic progressive external
ophthalmoplegia (arCPEO)Multiple deletions of mitochon-
drial DNA have been reported in numerous sporadic CPEO
cases or in families in which CPEO was clearly transmitted as
a recessive trait (Lamantea et al 2002).
Mitochondrial neurogastrointestinal encephalomyopathy
(MNGIE) This is an autosomal recessive disease character-
ized by the unusual combination of six features: (1) progres-
sive external ophthalmoplegia, (2) severe gastrointestinal
dysmotility, (3) cachexia, (4) peripheral neuropathy, (5) dif-
fuse leukoencephalopathy on brain MRI, due to altered
blood–brain barrier, and (6) evidence of mitochondrial dys-
function (histological, biochemical, or genetic abnormalities
of the mitochondria) (Hirano et al 1994). The mean age at
onset is 19 years, and the mean age at death is 37.6 years.
Gastrointestinal manifestations comprise the most prominent
and debilitating feature; painful gastrointestinal dysmotility
may cause gastroparesis, frequent diarrhea, and intestinal
pseudo-obstruction. Skeletal muscle biopsies reveal neuro-
genic changes and occasional ragged-red and cytochrome c
oxidase-deficient fibers, reflecting the neuropathy and mito-
chondrial myopathy. The peripheral neuropathy is predomi-
nantly demyelinating, but electrophysiological data have also
shown evidence of axonopathy in about one half of the pa-
tients. In the gastrointestinal system, histological studies have
revealed abnormalities of both the intestinal smooth muscle
and the enteric nervous system, thus accounting for the severe
gastrointestinal problems. In particular, studies of postmortem
tissues from MNGIE patients revealed a selective, profound
mtDNA depletion, and marked atrophy of the external layer of
the muscularis propria of the small intestine, consistent with a
visceral myopathy leading to the prominent gastrointestinal
involvement typical of this disorder (Giordano et al 2006,
2008). Later-onset and longer survival MNGIE patients have
been reported (Marti et al 2005).
Alpers-Huttenlocher hepatopathic poliodystrophy;
s en so ry - a t ax i a neuropa thy, dy sa r th r i a and
ophthalmoplegia (SANDO); and spinocerebellar ataxia-
epilepsy (SCAE)Anumber of recessive syndromes have been
associated with qualitative or quantitative mtDNA abnormal-
ities. These syndromes are all characterized by an association
with recessive mutations of POLG, the master gene of
mtDNA replication. Alpers-Huttenlocher hepatopathic
poliodystrophy is an early onset, fatal disease, characterized
by hepatic failure and intractable seizures, evolving into
epilepsia partialis continua and global neurologic deteriora-
tion. The liver dysfunction is usually progressive as well,
evolving from microvesicular steatosis with bile duct prolifer-
ation into cirrhosis. Childhood-onset or juvenile-onset autoso-
mal recessive, progressive sensory-ataxic syndromes, with or
without epilepsy, have been reported, more frequently in
families from Northern European countries. The association
of sensory ataxic neuropathy with dysarthria and
ophthalmoplegia (SANDO) defines some of these families,
but in other families, cerebellar signs, myoclonus, and seizures
are additional prominent findings. The use of valproate to
control epilepsy is contraindicated in these patients because
of their exquisite sensitivity to valproate hepatotoxicity, which
may lead to fatal acute hepatic failure (Davidzon et al 2005;
Gauthier-Villars et al 2001; Horvath et al 2006; Naviaux and
Nguyen 2005; Naviaux et al 1999; Tzoulis et al 2006).
A tentative classification of these entities has been pro-
posed (Copeland and Longley 2014), according to the follow-
ing nomenclature: Alpers-Huttenlocher hepatopathic
poliodystrophy (AHS), childhood myocerebrohepatopathy
spectrum (MCHS), myoclonic epilepsy myopathy sensory
ataxia (MEMSA), and the ataxia neuropathy spectrum
(ANS). It is however important to stress that these entities
constitute a continuous spectrum of syndromes with overlap-
ping features (Fig. 2), with the exception perhaps of AHS
which has rather specific clinical and neuroimaging
hallmarks.
Mitochondrial DNA depletion syndromes In contrast to
other types of mtDNA defects, mtDNA depletion syndrome
is a quantitative abnormality: there is paucity of mtDNA , but
the remaining mtDNA does not harbor any mutations or rear-
rangements. Mitochondrial DNA depletion syndrome is trans-
mitted as an autosomal recessive trait and is clinically and
genetically heterogeneous.
Some children present with myopathy, others with liver
failure in infancy, and some with multisystem involvement.
Consistent with the different phenotypes, mtDNA depletion
may affect either a specific tissue (most commonly muscle or
liver and brain) or multiple organs, including heart, brain, and
kidney.
Myopathic form Typically, affected children are born after an
uncomplicated pregnancy, although decreased fetal move-
ments are noted in some cases. A few patients had
arthrogryposis and clubfeet, but facial dysmorphic features
are rare. The patient usually presents in the first year of life
with feeding difficulty, failure to thrive, hypotonia, weakness,
and occasionally progressive external ophthalmoplegia. Death
is usually due to pulmonary insufficiency and infections, but
some patients survive into their teens (Moraes et al 1991;
Tritschler et al 1992). The clinical spectrum has now expand-
ed to include spinal muscular atrophy type 3-like presentation,
rigid spine syndrome, severe muscle weakness with marked
dystrophic alterations, encephalopathy, and seizures (Galbiati
et al 2006), and a milder myopathic phenotype without motor
regression and with longer survival (Oskoui et al 2006).
mtDNA depletion in muscle has been reported in patients with
early-onset myopathy, lactic acidosis, and renal proximal
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tubulopathy with nephrocalcinosis (Bourdon et al 2007). In
patients with earlier onset and rapid courses, all muscle fibers
have little or no immunoreactivity to DNA antibodies in mito-
chondria and are cytochrome c oxidase-deficient, whereas in
later-onset patients the pattern of involvement is mosaic; some
fibers appear normal, whereas others lack both COX activity
and mtDNA. Proliferation of mitochondria (ragged-red fibers)
is not a consistent feature, but their number can increase with
age. Biochemical defects of all complexes containing mtDNA-
encoded subunits are always present in muscle mitochondria.
Patients with mtDNA depletion in muscle tend to have elevat-
ed serum creatine kinase levels, ranging from 2 to 30 times the
upper limit of normal. This is an important clue for the diag-
nosis because increased serum creatine kinase is relatively un-
common in patients with other mitochondrial myopathies.
Encephalomyopathic forms Two forms have been reported,
both caused by a block of succinyl-CoA lyase activity in the
Krebs cycle. The first is characterized by high lactate in blood,
severe psychomotor retardation with muscle hypotonia, im-
paired hearing, and generalized seizures followed by knee
and hip contractures, finger and limb dystonia, and mild pto-
sis. Brain MRI is suggestive of Leigh syndrome. Moderate
mtDNA depletion (about 32%) has been documented in skel-
etal muscle (Carrozzo et al 2007; Elpeleg et al 2005;
Ostergaard et al 2007a). Mutations in the gene encoding the
ATP-dependent succinyl-CoA synthase (SCS) activity,
SUCLA2, are responsible for this form. The second, extreme-
ly severe form is due to mutations in SUCLG1, the gene
encoding the GTP-dependent isoform SUCLG1 (see below)
and is associated with combined muscle and liver mtDNA
depletion, dysmorphic features, connatal lactic acidosis, and
death in the first days of life (Ostergaard et al 2007b). Both
syndromes are hallmarked by methylmalonic aciduria, which
accumulates because of impaired conversion into succinyl-
CoA of propionyl-CoA, derived from the beta oxidation of
odd-number fatty acids. A large cohort of patients with muta-
tions in SUCLA2 and SUCLG1 has been recently described
(Carrozzo et al 2016), showing significantly longer survival in
SUCLA2 patients compared to SUCLG1 patients.
Hypertrophic cardiomyopathy and liver involvement were ex-
clusively found in patients with SUCLG1 mutations, whereas
epilepsy was much more frequent in patients with SUCLA2
mutations compared to patients with SUCLG1 mutations.
Finally, patients with mutations in the ABAT gene,
encoding 4-aminobutyrate aminotransferase have elevated
levels of GABA along with severe psychomotor retardation,
intractable seizures, hypotonia, and hyperreflexia, associated
with profound mtDNA depletion (Besse et al 2015). ABAT,
besides its role in GABA biosynthesis, encodes another com-
ponent of the SCS.
The mechanism of mtDNA depletion in mutations of the
SCS components is unclear but could be related to the
physical interaction of SCS with nucleoside diphosphate ki-
nase, NDPK, an enzyme involved in the salvage pathway of
mitochondrial nucleotides.
Hepatocerebral form In addition to patients with Alpers-
Huttenlocher syndrome, hepatic mtDNA depletion is seen in
some infants with liver failure (Mazziotta et al 1992). Onset of
symptoms is between birth and 6months; death usually occurs
within 1 year of age. The most common symptoms and signs
include persistent vomiting, failure to thrive, hypotonia, and
hypoglycemia associated with progressive neurologic symp-
toms. Histological changes on liver biopsy include fatty de-
generation, bile duct proliferation, fibrosis, and collapse of
lobular architecture. Generalized reduction in COX histo-
chemistry and decreased mitochondrial respiratory chain en-
zyme activities were found in the liver of a few patients. A
variant form of hepatocerebral mitochondrial DNA depletion
syndrome affects the Navajo people with a prevalence of 1 in
1600 live births, hence the termNavajo neurohepatopathy (Vu
et al 2001).
Molecular genetics
Numerous genes have been associated with syndromes caused
by mtDNA instability (Fig. 1) but a substantial fraction of
these conditions remain genetically undefined.
ANT1 Encoded by SLC25A4, ANT1 is the muscle-specific
isoform of the mitochondrial adenine nucleotide translocator,
and it is also expressed in heart and brain. Several mutations in
SLC25A4 have been linked to mitochondrial disorders and fall
into two distinct clinical phenotypes. The first is caused by
several single heterozygous mutations, and manifests as
adCPEO (Deschauer et al 2005; Kaukonen et al 2000;
Komaki et al 2002; Napoli et al 2001; Siciliano et al 2003).
The second consists of a relatively benign mitochondrial my-
opathy and cardiomyopathy phenotype that presents in child-
hood or early adulthood and is characterized by fatigue and
exercise intolerance, associated with recessive null mutations
(Echaniz-Laguna et al 2012; Korver-Keularts et al 2015;
Palmieri et al 2005; Strauss et al 2013). From the molecular
point of view, both dominant and recessive mutations lead to
the accumulation of multiple mtDNA deletions, and their clin-
ical course is relatively benign. However, de novo dominant
mutations in SLC25A4 have recently been identified by whole
exome sequencing in seven patients presenting with profound
congenital hypotonia and muscle weakness, leading to death
in the neonatal period. Profound mtDNA depletion and im-
pairment of ATP transport capacity is the hallmark of this
early onset form of ANT1-related disease (Thompson et al
2016). However, the reason why either recessive or dominant
mutations in a monomeric protein (Bamber et al 2007) give
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rise to such a wide spectrum of clinical and molecular pheno-
types is still unknown.
TWNK This gene (previously designated as C10orf2) en-
codes Twinkle, the mitochondrial DNA and RNA helicase in-
volved in replication of the mitochondrial genome.
Heterozygous mutations in this gene are responsible for
adCPEO (Spelbrink et al 2001) with accumulation of multiple
mtDNA deletions. Clinical presentations include CPEO, often
associated with proximal muscle and facial weakness, dyspha-
gia and dysphonia, mild ataxia, and peripheral neuropathy.
Symptoms are much more severe in a few homozygous mutant
patients described in consanguineous families. A specific, re-
cessive TWNK mutation is responsible for infantile onset
spinocerebellar ataxia, IOSCA (Nikali et al 2005), which is part
of the Finnish disease heritage. Onset usually is between 1 and
2 years of age. Patients suffer from a combination of ataxia,
athetosis, areflexia, muscle hypotonia, and severe epilepsy.
Other features such as ophthalmoplegia, hearing loss, and optic
atrophy appear later in the disease course. Some patients show
reduced mental capacity, and hypergonadotropic
hypogonadism may occur in girls. Morphologic studies reveal
sensory axonal neuropathy and progressive atrophy of the cer-
ebellum, brainstem and spinal cord (Koskinen et al 1994).
Besides infantile onset spinocerebellar ataxia, an Alpers-like
clinical phenotype has also been associated with recessive mu-
tations in TWNK (Fig. 2) (Hakonen et al 2007; Sarzi et al 2007).
Pol-gamma mutations The mitochondrial DNA polymerase
(pol-gamma) is essential for mitochondrial DNA replication
and proofreading-based repair. It is composed of a 140-kDa
catalytic subunit (pol-[gamma]A) and a 55-kDa accessory
subunit (pol-[gamma]B), which functions as a DNA binding
factor, increasing the processivity of the polymerase holoen-
zyme. The holoenzyme works as an A1B2 heterotrimer. The
catalytic subunit is encoded by POLG on chromosome 15q25,
whereas the accessory subunits are coded by POLG2 on chro-
mosome 17q.Mutations of POLG are a major cause of human
mitochondrial disease. So far more than 100 mutations in pol-
gamma have been reported (http://tools.niehs.nih.gov/polg).
This gene is the most frequent cause of adCPEO (50% of
the cases in our series) (Lamantea et al 2002; Van Goethem
et al 2001). In addition to CPEO, prominent features are se-
vere dysphagia and dysphonia and, occasionally, a movement
Fig. 1 Pathways involved in
mtDNA maintenance
Fig. 2 Scheme representing the continuous spectrum of clinical
phenotypes associated with mutations in mtDNA-maintenance-related
genes
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disorder including parkinsonism, cerebellar dysfunction, or
chorea (Luoma et al 2004). Mental retardation, hypogonadism
(including precocious menopause), and gastrointestinal
dysmotility may be additional findings (Filosto et al 2003;
Luoma et al 2004). The severity of the syndromes varies in
relation to the type of mutation.
Recessive mutations of POLG are also responsible for a
variety of other syndromes, including most of the autosomal
recessive CPEO cases (Lamantea et al 2002) and the appar-
ently sporadic CPEO cases associated with the accumulation
of multiple mt DNA deletions (Agostino et al 2003).
Recessive POLG mutations have been described in Alpers-
Huttenlocher syndrome (Davidzon et al 2005; Ferrari et al
2005; Naviaux and Nguyen 2004) associated with mtDNA
depletion. Mutations in POLG are also responsible for
SANDO (Van Goethem et al 2003) and SCAE syndromes
identified in Northern Europe (Van Goethem et al 2004;
Winterthun et al 2005; Horvath et al 2006). In several in-
stances, the same POLG mutations have been reported in
these different syndromes, suggesting that they form a contin-
uum of BPOLG-related,^ severe, recessive disorders (Fig. 2).
Two mutant alleles determining amino acid changes in the
spacer region of the pol-gammaA protein (p.Ala467Thr and
p.Trp748Ser) are often recurrent in these conditions, which
may help the diagnostic workout in suspected cases.
A few heterozygous dominant mutations have been identi-
fied in POLG2, in patients with adult-onset CPEO, cardiac
conduction defect, and increased creatine kinase (Longley
et al 2006; Walter et al 2010; Young et al 2011).
TFAM A homozygous mutation in TFAM has been found in
two siblings with a severe neonatal hepatic syndrome (Stiles
et al 2016) and profound mtDNA depletion in liver and skel-
etal muscle. The mutation (c.533C > T) affects proline 178
(p.Pro178Leu), which is important for the interaction with
the mtDNA minor groove. As a consequence of the mutation,
the interaction of TFAM with mtDNA is impaired, TFAM
undergoes degradation and nucleoids are reduced in number
and aggregate to form perinuclear clusters.
MGME1, DNA2, RNASEH1 In addition to the main constit-
uents of the mitochondrial replisome, i.e., Pol-gamma A and
B and the helicase Twinkle, several genes have been identified
which encode proteins involved in maturation of the newly
synthesized mtDNA strands and may also take part in some
mechanisms of mtDNA repair, notably long-patch base-exci-
sion repair (LP-BER). Some of these gene products, such as
the DNA flappase MGME1, are exclusively localised within
mitochondria. Others have a double localization, in both the
nucleus and mitochondria. For instance DNA2 and FEN1,
which are also involved in the processing of 5′ flap structures
occurring in DNA replication and LP-BER, and RNAseH1,
which specifically digests the RNA component of RNA/DNA
hybrids, formed during RNA priming of DNA templates.
Mutations in MGME1 (Kornblum et al 2013), DNA2
(Ronchi et al 2012) and RNASEH1 (Reyes et al 2015) have
recently been identified in patients with PEO and accumula-
tion of multiple mtDNA deletions. Whilst MGME1 and
RNASEH1 mutations are inherited as recessive traits, DNA2
mutations seem to be dominant. The onset is usually in adult-
hood, more rarely in childhood, and PEO is frequently com-
plicated by prominent weakness of the respiratory muscles,
leading to ventilatory insufficiency, ataxia with cerebellar at-
rophy and additional signs indicating the involvement of the
central and peripheral nervous systems.
RRM2B, TK2, DGUOK, andMPV17 These genes were ini-
tially associated with mtDNA depletion syndromes but allelic
variants were later linked to adult-onset disorders associated
with mtDNA multiple deletions, in most cases CPEO syn-
dromes (Fig. 2).
RRM2B encodes the small (regulatory) subunit of p53-
inducible ribonucleotide reductase, involved in the de novo
conversion of ribonucleoside diphosphates into the corre-
sponding deoxyribonucleoside diphosphates. Notably, this en-
zyme is localized in the cytosol, not in mitochondria, but in
non-proliferating tissues it plays a major role in supplying
deoxynucleotides for mtDNA replication. Heterozygous mu-
tations in RRM2B are a prominent cause of adCPEO (Fratter
et al 2011; Tyynismaa et al 2012). Recessive mutations in
RRM2B are typically found in infantile cases of myopathic
mtDNA depletion syndrome with renal proximal tubulopathy
(Bourdon et al 2007), but a single family was associatedwith a
recessive form of CPEO (Takata et al 2011). A clear correla-
tion between the clinical phenotype and the underlying genet-
ic defect was found in a relatively large cohort of patients
(Pitceathly et al 2012). Myopathy, bulbar dysfunction, and
fatigue were prominent symptoms, often associated with sen-
sorineural hearing loss and gastrointestinal disturbance.
Severe multisystem neurological disease was associated with
recessively inherited compound heterozygous mutations with
a mean age of disease onset at 7 years. Dominantly inherited
heterozygous mutations were associated with a milder pre-
dominantly myopathic phenotype.
TK2 is the mitochondrial deoxyribonucleoside kinase that
phosphorylates thymidine, deoxycytidine, and deoxyuridine.
Recessive mutations in TK2 have been associated with both
the myopathic form of mtDNA depletion syndrome and
CPEO with mtDNA multiple deletions (Tyynismaa et al
2012). Multiple deletions have also been reported in adult
myopathic patients with slowly progressive weakness and re-
spiratory failure (Alston et al 2013; Behin et al 2012; Paradas
et al 2013).
Similarly, recessive mutations in DGUOK, encoding the
mitochondrial deoxyguanosine kinase, were initially found
in association with the severe infantile hepatocerebral form
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of mtDNA depletion. Later, exome sequencing in adult pa-
tients revealed the presence of DGUOK mutations associated
with a spectrum of clinical phenotypes ranging from mito-
chondrial myopathy with or without CPEO, recurrent rhabdo-
myolysis, and adult-onset lower motor neuron syndrome with
mild cognitive impairment (Ronchi et al 2012). These patients
had accumulation of mtDNA multiple deletions in skeletal
muscle.
Finally, mutations in MPV17, encoding a small protein of
the inner mitochondrial membrane of unknown function, were
originally associated with hepatocerebral mtDNA depletion
(Spinazzola et al 2006), and later found in patients with
mtDNA multiple deletions and recessive adult-onset mito-
chondrial myopathy with CPEO, parkinsonism, and
leukoencephalopathy (Blakely et al 2012; Garone et al
2012a, b).
OPA1 andMFN2 OPA1 is a dynamin-like GTPase located in
the inner mitochondrial membrane involved in mitochondrial
fusion, cristae organization, and control of apoptosis. OPA1 is
linked to non-syndromic autosomal dominant optic atrophy
(DOA), a condition characterized by slowly progressive visual
loss starting in childhood, first described by the Danish oph-
thalmologist Paul Kjer in 1959. However, a few missense
mutations, clustered in the GTPase domain, are responsible
for a non-syndromic autosomal dominant optic atrophy
Bplus^ syndrome, consisting of a combination of DOA with
CPEO, peripheral neuropathy, ataxia, deafness (Amati-
Bonneau et al 2008; Hudson et al 2008), and multiple
sclerosis-like illness or spastic paraplegia (Yu-Wai-Man et al
2010). These patients have ragged-red and COX negative
muscle fibers, with paracrystalline inclusions filling abnor-
mally shaped mitochondria. In two large Italian families with
autosomal dominant OPA1 mutations, adCPEO was associat-
ed with parkinsonism in several patients, whereas symptom-
atic optic atrophy was absent in most of the affected individ-
uals (Carelli et al 2015). Remarkably, the BOPA1-plus^ pa-
tients harbor multiple mtDNA deletions and OXPHOS defi-
ciency in their skeletal muscle (Lodi et al 2011). The mecha-
nisms leading to the accumulation of multiple mtDNA dele-
tions in this condition are still unknown but indicate that mi-
tochondrial shape and mtDNA integrity are linked, possibly
through a mechanism controlling the structure and function of
nucleoids (Zeviani 2008).
Interestingly, a single family with DOA plus phenotype
without CPEO has been reported in association with a
MFN2 heterozygous missense mutation (c.629A > T,
p.D210V); these patients showed accumulation of mtDNA
multiple deletions in skeletal muscle (Rouzier et al 2012).
Thus, impaired fusion due to mutations in both OPA1 and
MFN2 proteins may lead to mtDNA instability and depletion
through novel mechanisms, which are sti ll under
investigation.
SPG7 SPG7 encodes for paraplegin, a component of the m-
AAA protease, an ATP-dependent proteolytic complex of the
mitochondrial inner membrane that degrades misfolded pro-
teins and regulates ribosome assembly (Nolden et al 2005).
Originally associated with autosomal recessive spastic para-
plegia (Casari et al 1998), SPG7 recessive mutations have
later been found in patients with CPEO and mtDNA multiple
deletions (Pfeffer et al 2014; Wedding et al 2014). Typically,
the clinical phenotype develops in mid-adult life with either
CPEO/ptosis and spastic ataxia, or a progressive ataxic disor-
der. The mechanism leading to multiple deletions remains
unclear.
AFG3L2 Two patients with indolent ataxia and CPEO with
two different heterozygous mutations in AFG3L2were recent-
ly identified (Gorman et al 2015). AFG3L2 encodes another
subunit of m-AAA protease which interacts with paraplegin,
and was originally associated with spinocerebellar ataxia.
Also in this case, the mechanism leading tomtDNA instability
is unknown.
Thymidine phosphorylase mutations in MNGIE Mapping
of the MNGIE trait on chromosome 22q13.32-qter (Hirano
et al 1998) has led to the identification of mutations in the
gene encoding thymidine phosphorylase (TYMP) as the cause
of the disease (Nishino et al 1999). Thymidine phosphorylase
is involved in the catabolism of pyrimidines by promoting the
phosphorolysis of thymidine into thymine and deoxyribose-
phosphate. Defects of thymidine phosphorylase result in sys-
temic accumulation of its substrates—thymidine and
deoxyuridine (Marti et al 2004; Spinazzola et al 2002).
In vitro studies have demonstrated that excess of thymidine
and deoxyuridine leads to deoxynucleotide pool imbalance
(Ferraro et al 2005), which in turn can cause mtDNA instabil-
ity (Pontarin et al 2006). This is reflected by the molecular
phenotype of mitochondrial neurogastrointestinal encephalo-
myopathy, which is characterized by both multiple deletions
and partial depletion of muscle mtDNA.
Pathogenetic considerations
The CPEO phenotype is commonly associated with single
mtDNA deletions in sporadic patients (Spinazzola and
Zeviani 2005). A pathogenetic role of multiple mtDNA dele-
tions in autosomal dominant or recessive CPEO is supported
by the evidence of tight segregation of the molecular lesions
with the onset and severity of the disease. For instance,
Lamantea and colleagues have reported that, in a series of
POLG-positive CPEO families, homozygous individuals ap-
peared more severely affected and showed the presence of
much higher amounts of multiple mtDNA deletions in muscle
than their heterozygous relatives (Lamantea et al 2002).
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Moslemi and colleagues have demonstrated close correlation
between the accumulation of deletions and the segmental
ragged-red cytochrome c oxidase-negative transformation of
muscle fibers (Moslemi et al 1996). These authors showed that
within a single cytochrome c oxidase-deficient muscle fiber
segment, only one single deletion could be detected.
However, different deletions were identified in different seg-
ments. These results indicate clonal expansion of a single de-
leted mtDNA in each cytochrome c oxidase-deficient muscle
fiber segment. A two-hit mechanism can, therefore, be hypoth-
esized, consisting of the combination of a nuclear factor that
somehow predisposes to mtDNA deletions, followed by clonal
expansion of each deleted mtDNA molecule in muscle and
other stable tissues (Moslemi et al 1996). Deletions are absent
in cultured fibroblasts, peripheral blood cells, and cultured
myoblasts but can be detected in stable tissues, including (be-
sides skeletal muscle) brain, heart, and in lesser amount, kidney,
and liver. Disturbances of the nucleotide pool available for
mtDNA replication, as well as abnormalities in either the mito-
chondrial helicase or mtDNA polymerase, are likely to affect
the rate or process of DNA replication, which could ultimately
lead to the exaggerated production of rearranged mtDNA mol-
ecules (Graziewicz et al 2004). In addition to large-scale rear-
rangements, increased frequency of mtDNA point mutations
have been reported in MNGIE (Nishigaki et al 2003). Several
somatic mutations, mostly T > C transitions preceded by 5′-An
sequences, were scattered throughout the mtDNA molecule of
tissues and cultured cells from MNGIE patients. Some muta-
tions were clearly pathogenic, as they predict loss or abnormal
function of mtDNA-encoded proteins or tRNA. The accumu-
lation of these mutations is likely to be due to next-nucleotide
effects and dislocation mutagenesis, as a consequence of in-
creased levels of mitochondrial deoxy-thymidine and deoxy-
uridine pools (Nishigaki et al 2003).
Finally, the mtDNA damage caused by POLGmutations in
Alpers-Huttenlocher syndrome, SANDO, and SCAE syn-
drome is unclear. Depletion of mtDNA in critical organs (liver
and brain) has been demonstrated in a few cases (Ferrari et al
2005; Tzoulis et al 2014), which may explain the early onset
and severity of these conditions.
Balance and control of the mitochondrial deoxynucleotide
pools are essential for the maintenance of mtDNA integrity
and copy number. Perturbation of this homeostatic control, as
determined by defects of dGK and TK2, and possibly of thy-
midine phosphorylase, RRM2B, and ANT1 as well, can lead
to mtDNA depletion or multiple deletions. In particular, dGK
and TK2 are involved in the salvage pathways of mitochon-
drial deoxynucleotides, which constitute the major source of
mtDNA precursors in stable tissues such as liver, brain, and
muscle. Although a role for MPV17 has been proposed in the
cellular response to metabolic stress and maintenance of nu-
cleotide pools (Dalla Rosa et al 2016; Spinazzola et al 2006),
its function remains largely unknown.
The identification ofOPA1mutations as a cause of mtDNA
multiple deletions in skeletal muscle, which is now extended
to the cognate mitochondrial fusion protein MFN2 (Rouzier
et al 2012), points to the role played bymitochondrial network
dynamics in mtDNA maintenance (Yu-Wai-Man and
Chinnery 2012; Zeviani 2008). Impaired mitochondrial fusion
in cells and in recombinant mouse models is indeed associated
with mtDNA instability and worsening of the phenotype ef-
fects of mtDNA mutations (Chen et al 2010). Likewise, mul-
tiple deletions associated with mutations in SPG7 (paraplegin)
and AFG3L2 indicate a causative association between
mtDNA instability and impaired protein quality control in
mitochondria.
Additional genes
The mechanisms leading to mtDNA instability are rather con-
troversial for several of the genes associated with the disease.
For instance, SUCLA1 and SUCLG1 encode for compo-
nents of the Krebs cycle and their role in the last step of the
mitochondria dNTPs salvage pathway, because their associa-
tion with NDPK, has been postulated but not conclusively
proven. Similarly, ABAT is involved in GABA biosynthesis
but also interacts with SCS and has been proposed to have a
role in dNTP salvage pathway.
Another gene with an unclear role in mtDNA maintenance
is FBXL4. This gene has been recently associated with early
onset encephalopathy with mtDNA depletion (Bonnen et al
2013; Gai et al 2013). FBXL4 encodes for F-box and leucine-
rich repeat 4 protein targeted to the intermembrane space of
mitochondria. Although pathogenic mutations are associated
with substantially decreased mtDNA content and mitochon-
drial respiratory chain deficiency in muscle and fibroblasts, its
role in mtDNA maintenance is still unclear.
Finally, a homozygous mutation in the humanGFER gene,
coding for a sulfhydryl oxidase (DRS) of the mitochondrial
intermembrane space, has been reported in an inbred
Moroccan family (Di Fonzo et al 2009). Three siblings were
affected by congenital cataract, progressive muscular hypoto-
nia, sensorineural hearing loss, and developmental delay.
Muscle biopsy showed scattered COX deficiency and
mtDNA multiple deletions. DRS is a protein involved in one
of the mitochondrial protein import pathways. The pathogenic
link between DRS mutation and mtDNA multiple deletions is
presently unknown.
Concluding remarks
The development of next-generation sequencing (NGS) technol-
ogies (whole exome sequencing andwhole genome sequencing)
and their use in the diagnostic workout formitochondrial disease
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has had a tremendous impact on the pace of gene discovery in
recent years, and a huge set of new genes have indeed been
associated with either mtDNA multiple deletions or mtDNA
depletion. Nevertheless, a substantial fraction of the cases asso-
ciated with mtDNA instability remains unsolved. This may be
due to a number of reasons. First, we now know that genes
encoding proteins whose function is not directly related to
mtDNA replication or repair, such as OPA1, MFN2, FBXL4,
can affect mtDNA metabolism. This consideration requires a
substantial expansion of the territory of gene hunting, well be-
yond that of the Busual suspects^. Second, mtDNA defects can
be due to sporadic, heterozygous mutations, affecting singleton
cases, as in the case of the recent identification of lethal de novo
mutations in ANT1 (Thompson et al 2016). These cases can
escape detection, particularly if the screening does not include
parents and direct relatives of the proband. Third, the mutation
can affect deep intronic regions, and may escape detection if ad
hoc gene panels, or whole exome sequencing, WES, are carried
out or are considered a benign variant. Fourth, in case of spo-
radic patients, oligo- or multi-genic inheritance cannot be ex-
cluded, which complicates the diagnostic work-up. Fifth, the
expression of a pathological phenotype may depend on dual or
multiple mechanisms, for instance the mtDNA haplogroup, the
gender, or behavioral habits. Finally, in several cases the func-
tion of the culprit gene is unknown, and the attribution of a
pathogenic role to these Bunknown factors^may not be obvious.
The accumulation ofmoreWES andwhole genome sequencing,
WGS, data in the human population and the systematic use of
trio sequencing will possibly reduce the gap between the bio-
chemical and genetic diagnosis, not only in the syndromes as-
sociated with mtDNA instability but in mitochondrial medicine
as a whole.
A tissue biopsy, typically muscle, remains the gold stan-
dard for the diagnosis of mtDNA instability syndromes.
However, in an increasing number of cases the syndromic
characterization is specific enough to consent the screening
of suspected genes, by ad hoc gene panels or WES, before
or alternative to the investigation of muscle biopsy. Muscle
and, in specific cases, liver biopsies should be performed in
the routine analysis for mitochondrial disease when the diag-
nosis cannot be confirmed by direct targeted DNA testing.
Functional in vitro assays in tissue (typically muscle) have
been the mainstay of diagnosis of mitochondrial disorders,
especially prior to the recent advances in genomics.
Functional assays remain important measures of mitochondri-
al function. All of the mitochondrial disease guidelines and
diagnostic criteria developed prior to the recent advances in
genetic techniques and understanding include results of such
biochemical studies to help establish a mitochondrial disease
diagnostic workup (Nishigaki et al 2003; Nishino et al 1999;
Nolden et al 2005; Oskoui et al 2006; Ostergaard et al 2007a).
These tests evaluate the various functions of the mitochon-
drial ETC or respiratory chain. Functional assays include
enzyme activities of the individual components of the ETC,
measurements of the activity of respiratory chain complexes
and ATP synthase, blue-native gel electrophoresis, measure-
ment of the presence of various protein components within
complexes and supercomplexes (achieved via western blots
and gel electrophoresis), and consumption of oxygen using
various substrates and inhibitors. In any case we recommend
that these assays should be carried out in specialized centers,
as they require ad hoc expertise and standardized, verified and
complex technologies and diagnostic protocols.
As for the majority of mitochondrial disorders, no treat-
ment is currently available for disease associated with
mtDNA instability. However, it has been recently demonstrat-
ed in mouse models knockout for Tymp and knockin for the
Tk2 H126N mutation that the supplementation of deoxyribo-
nucleotides can effectively correct mtDNA depletion (Camara
et al 2014; Garone et al 2014). Albeit preliminary, these new
experimental approaches open the possibility for ad hoc ther-
apies for diseases due to mtDNA instability.
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